Indications for treatment: Is observation or chemotherapy alone a reasonable approach in the management of low-grade gliomas?

Seminars in Radiation Oncology

Volumn 25, Issue 3, 2015, Pages 203-209

  Schaff, Lauren R ^a   Lassman, Andrew B ^a,b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CHEMORADIOTHERAPY; DISEASE SURVEILLANCE; GLIOMA; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT INDICATION; ADJUVANT CHEMOTHERAPY; BRAIN NEOPLASMS; OBSERVATION;

BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; GLIOMA; HUMANS; OBSERVATION;

EID: 84943183801     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2015.02.008     Document Type: Review

References (72)

1. Louis DN, Ohgaki H, Wiestler OD, et al: WHO Classification of Tumours of the Central Nervous System, 4th ed. Lyon: International Agency for Research on Cancer, 2007
2. Buckner JC, Shaw EG, Pugh SL, et al: R9802: phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: results by histologic subtype. Neuro Oncol 16(suppl 5):v11, 2014. [abstract AT-3 (oral presentation update)]
3. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
4. Levin VA, Edwards MS, Wright DC, et al: Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64:237-244, 1980
5. Karim AB, Afra D, Cornu P, et al: Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52:316-324, 2002
6. van den Bent MJ, Afra D, de Witte O, et al: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985-990, 2005
7. Pignatti F, van den Bent M, Curran D, et al: Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076-2084, 2002
8. Daniels TB, Brown PD, Felten SJ, et al: Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys 81:218-224, 2011
9. Shaw EG, Berkey B, Coons SW, et al: Recurrence following neurosurgeondetermined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg 109:835-841, 2008
10. Smith JS, Chang EF, Lamborn KR, et al: Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26:1338-1345, 2008
11. Schiff D, Brown PD, Giannini C: Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 69:1366-1373, 2007
12. Baumert B, Mason W, Ryan G, et al: Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: a randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). J Clin Oncol 31 2013. [abstract: 2007]
13. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
14. Ino Y, Betensky RA, Zlatescu MC, et al: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839-845, 2001
15. Wick W, Hartmann C, Engel C, et al: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874-5880, 2009
16. Cairncross G, Wang M, Shaw E, et al: Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337-343, 2013
17. van den Bent MJ, Brandes AA, Taphoorn MJ, et al: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344-350, 2013
18. Iwamoto FM, Nicolardi L, Demopoulos A, et al: Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol 88:293-298, 2008
19. Jenkins RB, Blair H, Ballman KV, et al: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852-9861, 2006
20. Mariani L, Deiana G, Vassella E, et al: Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol 24:4758-4763, 2006
21. Kujas M, Lejeune J, Benouaich-Amiel A, et al: Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 58:322-326, 2005
22. Vogelbaum MA, Wang M, Peereboom DM, et al: RTOG 0131: phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas-updated survival and progression free survival analysis. Neuro-Oncol 14:vi75-vi76, 2012. [abstract no: 56]
23. Everhard S, Kaloshi G, Criniere E, et al: MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60:740-743, 2006
24. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
25. Rivera AL, Pelloski CE, Gilbert MR, et al: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12:116-121, 2010
26. Noushmehr H, Weisenberger DJ, Diefes K, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522, 2010
27. van den Bent MJ, Gravendeel LA, Gorlia T, et al: A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res 17:7148-7155, 2011
28. Sanson M, Marie Y, Paris S, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154, 2009
29. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009
30. Houillier C, Wang X, Kaloshi G, et al: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560-1566, 2010
31. van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al: MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res 19:5513-5522, 2013
32. Labussiere M, Idbaih A, Wang XW, et al: All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74:1886-1890, 2010
33. Cairncross JG, Wang M, Jenkins RB, et al: Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783-790, 2014
34. Komine C, Watanabe T, Katayama Y, et al: Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 13:176-184, 2003
35. Li J, Bentzen SM, Li J, et al: Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 71:64-70, 2008
36. Lieberman AN, Foo SH, Ransohoff J, et al: Long term survival among patients with malignant brain tumors. Neurosurgery 10:450-453, 1982
37. Prabhu RS, Won M, Shaw EG, et al: Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. J Clin Oncol 32:535-541, 2014
38. Li J, Bentzen SM, Renschler M, et al: Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 25:1260-1266, 2007
39. Douw L, Klein M, Fagel SS, et al: Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8:810-818, 2009
40. Klein M, Heimans JJ, Aaronson NK, et al: Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360:1361-1368, 2002
41. Laack NN, Brown PD, Ivnik RJ, et al: Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 63:1175-1183, 2005
42. DeAngelis LM, Delattre JY, Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 39:789-796, 1989
43. van den Bent MJ, Jaeckle K, Baumert B, et al: RTOG 9802: good wines need aging. J Clin Oncol 31:653-654, 2013
44. Mulholland S, Pearson DM, Hamoudi RA, et al: MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. Int J Cancer 131:1104-1113, 2012
45. Turcan S, Rohle D, Goenka A, et al: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479-483, 2012
46. Surma-aho O, Niemela M, Vilkki J, et al: Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56:1285-1290, 2001
47. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: central nervous system cancers (Version 2.2014), 2014. Available at: http://www.nccn.org/. Accessed January 13, 2015.
48. Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013-2021, 1994
49. Buckner JC, Gesme Jr. D, O'Fallon JR, et al: Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251-255, 2003
50. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 46:203-207, 1996
51. Paleologos NA, Vick NA, Kachoris JP: Cehmotherapy for low-grade oligodendrogliomas? Ann Neurol 36:294-295, 1994
52. Stege EM, Kros JM, de Bruin HG, et al: Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103:802-809, 2005
53. Lebrun C, Fontaine D, Bourg V, et al: Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 14:391-398, 2007
54. Soffietti R, Ruda R, Bradac GB, et al: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43: 1066-1073, 1998
55. Frenay MP, Fontaine D, Vandenbos F, et al: First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure lowgrade astrocytomas. Eur J Neurol 12:685-690, 2005
56. Higuchi Y, Iwadate Y, Yamaura A: Treatment of low-grade oligodendroglial tumors without radiotherapy. Neurology 63:2384-2386, 2004
57. van den Bent MJ, Chinot O, Boogerd W, et al: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14:599-602, 2003
58. Pace A, Vidiri A, Galie E, et al: Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14:1722-1726, 2003
59. Quinn JA, Reardon DA, Friedman AH, et al: Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21:646-651, 2003
60. Kaloshi G, Benouaich-Amiel A, Diakite F, et al: Temozolomide for lowgrade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831-1836, 2007
61. Pouratian N, Gasco J, Sherman JH, et al: Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 82:281-288, 2007
62. Tosoni A, Franceschi E, Ermani M, et al: Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 89:179-185, 2008
63. Sanson M, Cartalat-Carel S, Taillibert S, et al: Initial chemotherapy in gliomatosis cerebri. Neurology 63:270-275, 2004
64. Levin N, Gomori JM, Siegal T: Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. Neurology 63:354-356, 2004
65. Brada M, Viviers L, Abson C, et al: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14:1715-1721, 2003
66. Kesari S, Schiff D, Drappatz J, et al: Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15:330-337, 2009
67. Abrey LE, Louis DN, Paleologos N, et al: Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 9:314-318, 2007
68. Panageas KS, Iwamoto FM, Cloughesy TF, et al: Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol 14:761-767, 2012
69. Lassman AB: Success at last: a molecular factor that informs treatment. Curr Oncol Rep 15:47-55, 2013
70. Fisher BJ, Lui J, Macdonald DR, et al: A phase II study of a temozolomidebased chemoradiotherapy regimen for high-risk low-grade gliomas: preliminary results of RTOG 0424. J Clin Oncol 31 2013. [Abstract 2008]
71. Iwadate Y, Matsutani T, Hasegawa Y, et al: Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy. J Neurooncol 102:443-449, 2011
72. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008